Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endocrine pathology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Endocrine pathology. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-001370-88 Sponsor Protocol Number: IBCSG 35-07/ BIG 1-07 Start Date*: 2007-11-06
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor...
    Medical condition: Postmenopausal women who are disease-free following 4-6 years of prior adjuvant endocrine therapy with selective estrogen receptor modulator(s) (SERM) and/or aromatase inhibitor(s) (AI) for endocri...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed) DK (Completed) GB (Completed) ES (Completed) SI (Completed) GR (Completed) AT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007348-32 Sponsor Protocol Number: CSOM230D2203 Start Date*: 2009-05-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin
    Medical condition: The following tumors are included: 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma, 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003553-19 Sponsor Protocol Number: IBCSG59-19/BIG18-02 Start Date*: 2019-06-25
    Sponsor Name:International Breat Cancer Study Group (IBCSG)
    Full Title: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2...
    Medical condition: patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005326-29 Sponsor Protocol Number: IBCSG_41-13 Start Date*: 2013-11-11
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine r...
    Medical condition: Premenopausal patients with histologically confirmed locally advanced breast cancer and with primary tumor of ER+/PgR+ and HER2 negative or not amplified.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001488-60 Sponsor Protocol Number: WSG-AM11 Start Date*: 2020-07-09
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus stand...
    Medical condition: HR+/HER2- early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000287-29 Sponsor Protocol Number: ET-FES00119 Start Date*: 2014-08-13
    Sponsor Name:Università del Piemonte Orientale
    Full Title: EARLY PREDICTION OF EFFICACY OF ENDOCRINE THERAPY IN BREAST CANCER: PILOT STUDY AND VALIDATION WITH 18F FLUOROESTRADIOL (FES) PET/CT
    Medical condition: Patients with histologically or cytologically confirmed ER-positive MBC at first evidence of metastatic disease.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016453-17 Sponsor Protocol Number: IEO S504/409 Start Date*: 2009-12-17
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Phase II study of preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide � trastuzumab and endocrine therapy for inflammatory breast cancer
    Medical condition: Inflammatory breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021980 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004753-95 Sponsor Protocol Number: DBTY 000/Capsulin/1Mar Start Date*: 2006-03-27
    Sponsor Name:Diabetology Ltd
    Full Title: A Phase II, Dose Ranging Single Centre, Single Blind, Parallel-group, Controlled Study of the Safety, Tolerability and Effects on Metabolic Control of an Oral Insulin Formulation in a Type II Diabe...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002553-30 Sponsor Protocol Number: EORTC-1745-ETF-BCG Start Date*: 2018-11-28
    Sponsor Name:European Organisation for research and treatment of Cancer
    Full Title: A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cance (APPALACHES)
    Medical condition: Localized ER+ breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006290 Breast and nipple neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) SE (Completed) ES (Ongoing) DE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-004942-14 Sponsor Protocol Number: IJB-LOB-2019 Start Date*: Information not available in EudraCT
    Sponsor Name:Institut Jules Bordet
    Full Title: Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast
    Medical condition: ER-positive/HER2-negative invasive lobular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073096 Invasive lobular breast carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003434-18 Sponsor Protocol Number: IBCSG 32-05/ BIG 1-05 Start Date*: 2006-05-04
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Phase III Trials Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suit...
    Medical condition: Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrin...
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) SI (Completed) IT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001984-10 Sponsor Protocol Number: WO42312 Start Date*: 2020-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ENDOCRINE MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ES...
    Medical condition: Estrogen receptor (ER)-positive, HER2 negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced or metastatic setting
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001896-35 Sponsor Protocol Number: PUMA-NER-6203 Start Date*: 2020-01-30
    Sponsor Name:Puma Biotechnology, Inc
    Full Title: An Open-Label Phase 2 Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
    Medical condition: HER2 amplified (HER2+) stage 1 through stage 4 primary adenocarcinoma of the breast
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000129-28 Sponsor Protocol Number: GO42784 Start Date*: 2021-08-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WIT...
    Medical condition: Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001462-17 Sponsor Protocol Number: WSG-AM06 Start Date*: 2012-03-29
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
    Medical condition: Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002626-59 Sponsor Protocol Number: 26-02/BIG 4-02 Start Date*: 2005-11-21
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy
    Medical condition: Premenopausal women with histologically proven, resected breast cancer with ER and/or PgR positive tumors for whom there is an uncertain role for adding chemotherapy to the adjuvant treatment program
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057654 LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000419-17 Sponsor Protocol Number: AFT-38 Start Date*: 2017-08-25
    Sponsor Name:Alliance Foundation Trials, LLC
    Full Title: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatm...
    Medical condition: HER2 Positive Breast Cancer Estrogen Receptor Positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003460-27 Sponsor Protocol Number: 2021-12964 Start Date*: 2022-01-04
    Sponsor Name:Radboudumc
    Full Title: CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in primary aldosteronism
    Medical condition: Primary Aldosteronism
    Disease: Version SOC Term Classification Code Term Level
    20.1 10014698 - Endocrine disorders 10036692 Primary hyperaldosteronism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002323-38 Sponsor Protocol Number: GBG105GeparPiPPa Start Date*: 2022-08-29
    Sponsor Name:German Breast Group
    Full Title: A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-pos...
    Medical condition: Patients with early breast cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 13 05:50:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA